{"groups":[{"description":"Pevonedistat 20 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.","id":"FG000","title":"Dose Level 1"},{"description":"Pevonedistat 40 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.","id":"FG001","title":"Dose Level 2"},{"description":"Pevonedistat 60 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.","id":"FG002","title":"Dose Level 3"},{"description":"Pevonedistat at the maximum tolerated dose determined in the dose levels given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.","id":"FG003","title":"Dose Expansion"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Disease progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}